中国创新药出海再现大单!7月28日,恒瑞医药(600276)宣布与葛兰素史克公司(GSK)达成合作协议,双方将共同开发至多12款创新药物。协议包含一款潜在同类最优PDE3/4抑制剂(HRS-9821)的授权许可,该产品目前正处于慢性阻塞性肺疾病(COPD)治疗的临床开发阶段;其余11个项目将由恒瑞医药主导研发,最晚至完成I期临床试验,GSK可行使优先选择权。如果所有项目均获得行使选择权且所有里程碑...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.